Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

A Duluth teenager with terminal cancer celebrated her birthday and high school graduation early this month with a ...

A study identified a link between sex hormones and renal cell carcinoma, suggesting potential new treatment strategies.

Ipsen's 2024 dividend per share amounted to EUR 1.20. We view Ipsen's shareholder distributions as mixed as many other biotechnology companies under our coverage do not pay dividends. We anticipate ...

Learn more about whether Amneal Pharmaceuticals, Inc. or HUTCHMED (China) Limited is a better investment based on AAII's A+ ...

Learn more about whether Corcept Therapeutics Incorporated or HUTCHMED (China) Limited is a better investment based on AAII's ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

A clinical trial demonstrates that personalised cancer vaccines effectively target mutations in high-risk kidney cancer, ...